A COMPARISON OF QUALITY OF LIFE AND OUTCOMES OF ENDOSCOPIC AND CONVENTIONAL SEPTOPLASTY
No Thumbnail Available
Date
2018
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Sağlık Bilimleri Üniversitesi İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Kliniği, İzmir, Turkey 2Manisa Celal Bayar Üniversitesi, Kulak Burun Boğaz Hastalıkları Anabilim Dalı, Manisa, TurkeySUMMARYObjective: Endoscopic septoplasty (ES) is a minimally invasive surgical technique for the nasal septal deviation. The purpose of thisstudy was to compare the quality of life and outcomes of patients who underwent conventional septoplasty (CS) and ES without additionalnasal surgeries.Methods: A total of 36 patients were selected among patients who underwent CS, and 35 sex- and age-matched patients who underwentES were enrolled in the study. Visual Analogue Scale (VAS) and Nasal Obstruction Symptom Evaluation (NOSE) scores were used tocollect the patient’s quality of life at the time of diagnosis and 3 months after CS and ES. The complication rates, duration of surgery andhospital stay were comparatively analyzed.Results: Preoperative VAS and NOSE scores were not statistically different in both groups (p=0.731, p=0.899; respectively). The VASand NOSE scores were significantly improved postoperatively (pCS-VAS<0.001, pES-VAS<0.001; pCS-NOSE<0.001, pES-NOSE<0.001; respectively);however, no significant difference was observed when the improvements of VAS and NOSE scores compared between CS and ES groups(p=0.307, p=0.461; respectively). Intraoperative flap laceration and intra/postoperative hemorrhage were in the favor of patients whounderwent ES (p=0.031, p=0.035; respectively). However, duration of surgery and hospital stay were lower in ES group compared to CSgroup (p<0.001, p=0.004; respectively).Conclusion: In selected cases, ES is a useful surgical technique in terms of complication rates, duration of surgery and hospital stay.Nevertheless, improvement of the quality of life was similar in patients underwent CS and ES.